Investigational drug · Phase 2
ARO-RAGE
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Asthma.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 1, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
3
Any phase or sponsor naming "ARO-RAGE"
First trial start
2022
Jun 29, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ARO-RAGE", any sponsor or status.
Conditions studied
As listed on its trial records.
- Asthma
Approved drugs for the same conditions: Asthma · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "ARO-RAGE" as an intervention, largest first.
- Study of ARO-RAGE in Healthy Subjects and Patients With Inflammatory Lung DiseasePivotal-lookingCompleted
Arrowhead PharmaceuticalsIndustry
NCT05276570 · 127 participants · Start Jun 29, 2022 · Primary completion Apr 16, 2025
Drug: ARO-RAGE; Placebo · For: Asthma
Sites: Nedlands, Australia; Auckland, New Zealand; Krakow, Poland · 8 sites in all
Arrowhead PharmaceuticalsIndustry
NCT05533294 · 43 participants · Start Nov 29, 2022 · Primary completion Feb 8, 2024
Drug: ARO-RAGE Injection; Placebo · For: Asthma
Sites: Grafton, New Zealand
Arrowhead PharmaceuticalsIndustry
NCT07241546 · 36 participants (planned) · Start Mar 30, 2026 · Primary completion Dec 2027
Drug: ARO-RAGE; Placebo · For: Asthma
Sites: Vancouver, Canada; Calgary, Canada; Edmonton, Canada · 6 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Inhaled siRNA therapy targeting RAGE for pulmonary inflammation: a first-in-human randomized trial.
O'Carroll M, Kasahara D, Huetsch J, et al. · Nat Med 2026
Also in development for Asthma
- CM512Phase 39 trials
Keymed Biosciences Co.Ltd · Chronic Rhinosinusitis With Nasal Polyposis, Chronic Spontaneous Urticaria (CSU), Asthma
- LunsekimigSAR443765Phase 39 trials
Sanofi · Asthma, Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps
- GSK5784283Phase 38 trials
GSK · Pulmonary Disease, Chronic Obstructive, Asthma, Nasal Polyps
- PF-07275315tilrekimigPhase 38 trials
Pfizer · Atopic Dermatitis, Asthma, Moderate to Severe Chronic Obstructive Pulmonary Disease
- MG-K10Humanized Monoclonal AntibodyPhase 36 trials
Shanghai Mabgeek Biotech.Co.Ltd · Dermatitis, Atopic, Chronic Urticaria, Idiopathic, Atopic Dermatitis
- SHR-1905Phase 36 trials
Guangdong Hengrui Pharmaceutical Co., Ltd · Asthma, Chronic Rhinosinusitis With Nasal Polyps, Moderate-to-severe Atopic Dermatitis
- TozorakimabMEDI3506Phase 36 trials
AstraZeneca · Chronic Obstructive Pulmonary Disease (COPD), Asthma, Viral Lung Infection and Acute Respiratory Failure
- TQC2731Phase 35 trials
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. · Asthma, Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.